{"success":true,"data":{"pressRelease":{"id":"179455","rtpr_id":"nPn3h5qhca-20261026","ticker":"HURA","exchange":"NASDAQ","all_tickers":["HURA"],"title":"TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma","author":"PR Newswire","published_at":"2026-10-26T11:30:00.831Z","article_body":"TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma\nPR Newswire\n\nTAMPA, Fla., Oct. 26, 2026\n\nPreliminary results demonstrate major objective tumor responses in first 3\npatients at 6 months\n\nCompany to host a webcast today, October 26, 2026, at 8:30 am ET\n\nTAMPA, Fla., Oct. 26, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:\nHURA) (\"TuHURA\" or the \"Company\"), a Phase 3 immuno-oncology company\ndeveloping novel therapeutics to overcome resistance to cancer immunotherapy,\ntoday announced initial data from the first three patients in its open-label\nstudy of IFx-2.0 as an adjunctive therapy to Keytruda® in first-line\ntreatment of metastatic Merkel Cell Carcinoma (MCC). Results showed that each\npatient achieved a major objective anti-tumor response, with all three\nresponses meeting the criteria for partial response (PR) under RECIST v.1.1\ncriteria. All responses were durable, as each of the responses were ongoing at\nthe protocol-specified six-month assessment.\n\nThe Phase 1b/2a trial of IFx-2.0 is a multicenter, open-label trial designed\nto assess the safety and feasibility of IFx-2.0 as adjunctive therapy to\nKeytruda® (pembrolizumab) when administered into deep seated and/or bulky\ntumors accessible with CT or ultrasound guided administration in the\nfront-line treatment of adult patients with metastatic MCC. The trial is\ndesigned to initially enroll a total of nine patients with visceral tumors\nincluding hepatic, pulmonary, or retroperitoneal or other deep seated\nlocations using CT or ultrasound guided administration where standard-size\ninjection needles are unable to effectively administer the intended dose of\nIFx-2.0.\n\nEach patient received IFx-2.0 (0.1 mg) injected into a single deep-seated or\nbulky tumor once a week for three weeks. Within 48 hours of the first IFx-2.0\ninjection, patients received Keytruda®, followed by Keytruda® every three\nweeks until the earlier of disease progression, toxicity, or 2 years.\nKeytruda® is approved as the front-line standard of care for patients with\nadvanced or metastatic MCC.\n\nThe primary endpoint of the study is safety and feasibility of IFx-2.0 therapy\nevaluated 28 days following the last dose of IFx-2.0, which is 49 days from\nthe first IFx-2.0 infusion. The study will also evaluate key secondary\nendpoints, including efficacy per RECIST1.1 criteria at three and six months.\n\n\"While preliminary and only reported in 3 patients, these results highlight\nthat it is feasible to utilize CT or ultrasound guided administration of\nIFx-2.0 safely to patients with large bulky and or deep-seated tumors. This is\nalso the first time we have administered IFx-2.0 with Keytruda® in the front\nline treatment setting of patients with metastatic MCC and may serve as a\nproxy to the potential response rates in the ongoing randomized placebo\ncontrolled Phase 3 trial, which is also being conducted in the front line\ntreatment of patients with advanced or metastatic MCC as an adjunct with\nKeytruda®,\" said Dr. James Bianco, President and Chief Executive Officer at\nTuHURA Biosciences. \"Approximately 30% of patients with metastatic MCC present\nwithout cutaneous or superficial nodal involvement. If we continue to see this\nhigh response rate in patients in this trial, we will explore the potential to\nexpand the number of patients in the trial and discuss with the FDA its\npotential to supplement the ongoing Phase 3 trial, should that study\nsuccessfully meet the primary endpoint. We look forward to additional patient\ndata in the coming months, and we will seek to present the data at an\nappropriate scientific conference next year.\"\n\nWebcast Information\n\nTuHURA will host a webcast today, October 26, 2026, at 8:30AM Eastern Time, to\ndiscuss the initial data from the open label Phase 1b/2a study of IFx-2.0.\n Investors and interested stakeholders may access the webcast by clicking\nHERE\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4805907-1&h=3695431808&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Ftuhura-biosciences-data-call-esmo-oct2026.open-exchange.net%2F___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQzZjFlNDNlOTU0YmIzM2YwN2Y4MWFjNjE2ZWYyZmZlOjc6MTcxMjo3NmZkZjZmMDQ5NWI2ZDRmOGE5MDYzNGEyY2Q2NTUwOGQwNGRhZTc4NzkxMDhkMzdkNTdmMWM4Yzg3ZmUyNGRiOnA6VDpG&a=HERE)\n.\n\nA replay of the webcast will be available on the Events\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4805907-1&h=83393492&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fir.tuhurabio.com%2Fnews-events%2Fevents___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQzZjFlNDNlOTU0YmIzM2YwN2Y4MWFjNjE2ZWYyZmZlOjc6YzdiZDo1N2MzMTAyNjU0NjlhMGRhMzljMDRlODY3MzU0NGJmZDJjNmZlNzk3NDg4OGQwNzE1YWYxMjBkYTA0NTFiNTFlOnA6VDpG&a=the+Events)\n portion of the Company's Investor Relation's website.\n\nAbout TuHURA Biosciences, Inc.\n\nTuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 immuno-oncology company\ndeveloping novel technologies to overcome primary and acquired resistance to\ncancer immunotherapy, two of the most common reasons cancer immunotherapies\nfail to work or stop working in the majority of patients with cancer.\n\nTuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary\nresistance to checkpoint inhibitors. TuHURA has initiated a single randomized\nplacebo-controlled Phase 3 registration trial of IFx-2.0 administered as an\nadjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus\nplacebo in first-line treatment for advanced or metastatic Merkel Cell\nCarcinoma.\n\nIn addition to its innate immune agonist product candidates, TuHURA is\ndeveloping TBS-2025, its VISTA-inhibiting mAb in a Phase 1b clinical trial in\npatients with mutNPM1 r/r AML, a molecularly defined subgroup that represents\napproximately 35% of patients with AML. TuHURA is also leveraging its Delta\nOpioid Receptor technology to develop first-in-class, bi-specific,\nbi-functional antibody drug conjugates (ADCs) targeting Myeloid-Derived\nSuppressor Cells to inhibit their immune-suppressing effects on the tumor\nmicroenvironment to prevent T cell exhaustion and acquired resistance to\ncheckpoint inhibitors and cellular therapies.\n\nFor more information, please visit www.tuhurabio.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4805907-1&h=84675304&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4767859-1%26h%3D308710934%26u%3Dhttp%253A%252F%252Fwww.tuhurabio.com%252F%26a%3Dwww.tuhurabio.com___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmRkZDMyYWMyOWNlOTIyZTVkNDQzOWU3MjZiOTA4NzQ2Ojc6NjAxNzphYmQ1NzU5MzE5NjNiNjExODUzZGRmMTAwMzQ2MjliM2U2M2VlYmJjY2U0ZWEwZTMxNTY1MjdjM2VmODYxNTNlOnA6RjpG&a=www.tuhurabio.com)\n and connect with TuHURA on Facebook, X, and LinkedIn.\n\nCautionary Statement Regarding Forward-Looking Statements\nThis press release contains certain \"forward-looking statements\" within the\nmeaning of, and subject to the safe harbor created by, Section 27A of the\nSecurities Act of 1933, as amended, Section 21E of the Securities Exchange Act\nof 1934, as amended, and the Private Securities Litigation Reform Act of 1995.\nThese forward-looking statements are based only on our current beliefs,\nexpectations and assumptions regarding the future of our business, future\nplans and strategies, projections, anticipated events and other future\nconditions. In some cases, you can identify these statements by\nforward-looking words such as \"believe,\" \"may,\" \"will,\" \"estimate,\"\n\"continue,\" \"anticipate,\" \"intend,\" \"could,\" \"should,\" \"would,\" \"project,\"\n\"plan,\" \"expect,\" \"goal,\" \"seek,\" \"future,\" \"likely,\" or the negative or\nplural of these words or similar expressions. Our statements in this press\nrelease regarding our ongoing Phase 3 study of IFx2.0 are an example of such\nforward-looking statements. You are cautioned that such statements are not\nguarantees of future performance and that actual results or developments may\ndiffer materially from those set forth in these forward-looking statements.\nFactors that could cause actual results to differ materially from these\nforward-looking statements include, among others, the risks associated\nconducting the ongoing Phase 3 study of IFx.20 and the general risks\nassociated with continuing the development of IFx2.0 and TBS 2025; risks\nrelated to patient enrollment, trial design, data outcomes and regulatory\ninteractions; uncertainty regarding the timing and likelihood of regulatory\napprovals; and the other risks described from time to time in detail in the\nCompany's Annual Report on Form 10-K for the fiscal year ended December 31,\n2025, as filed on March 31, 2026, and TuHURA's other reports and filings with\nthe SEC from time to time, which are available on TuHURA's website and at\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4805907-1&h=1954557226&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4789062-1%26h%3D1314921347%26u%3Dhttps%253A%252F%252Fprotect.checkpoint.com%252Fv2%252Fr01%252F___https%253A%252Fedge.prnewswire.com%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4772576-1%2526h%253D4152424364%2526u%253Dhttps%25253A%25252F%25252Fprotect.checkpoint.com%25252Fv2%25252Fr01%25252F___https%25253A%25252Fedge.prnewswire.com%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4690122-1%252526h%25253D1678506417%252526u%25253Dhttps%2525253A%2525252F%2525252Fprotect.checkpoint.com%2525252Fv2%2525252Fr01%2525252F___http%2525253A%2525252F%2525252Fwww.sec.gov%2525252F___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozODlkNDA2NjQzMDliNmJjZjNmYjc4MzgxMDU3YTlhMDo3OjVlN2M6MWRiMmJmY2RjNWFmMjdmMmZmOTBhNDM3YTAwNjRkM2E4OGM4ZWY2NDJmY2ExZWFlMTIwOWVkN2JhNTM1ZjcxZTpwOlQ6Rg%252526a%25253Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjdmODdiYmY0NjY2NzU4NzgzZWIyNDI3ODg4MTZiMGVlOjc6MDIyZDplNDhjNWE4M2FhNjI2OTc4MDc0ZjUzNTY2YzA1YzgzN2MwZmQ2ZDIxMTc1N2U3ODZhODk2NzQzZjc4MzY0MTNkOnA6RjpG%2526a%253Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjYwOTNjNzI3MDdjNDk5NmFhYzcxYjZmMDdjODE4ZDA0Ojc6ZTU5MzozZjQ1ZDAzYmViZmQ0MzliMGZkZjA5NDJhMmY3OTQ0MWQ4ZTBmNWJmZmM5MWFjZWVkNWIxNzA4ZDA1Nzc3ZjgwOnA6RjpG%26a%3D%25C2%25A0___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmRkZDMyYWMyOWNlOTIyZTVkNDQzOWU3MjZiOTA4NzQ2Ojc6ODE0ZDo0MDZjM2RjNzllMTJjNjNhZjEyZTljMjY0Nzk1MGJjOWI2NzRjN2RhYTVmNTNiN2U0MzJjYzM4NTZhOTA2MTFmOnA6RjpG&a=%C2%A0)\nwww.sec.gov\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4805907-1&h=3293196567&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4789062-1%26h%3D80447454%26u%3Dhttps%253A%252F%252Fprotect.checkpoint.com%252Fv2%252Fr01%252F___https%253A%252Fedge.prnewswire.com%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4772576-1%2526h%253D4152424364%2526u%253Dhttps%25253A%25252F%25252Fprotect.checkpoint.com%25252Fv2%25252Fr01%25252F___https%25253A%25252Fedge.prnewswire.com%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4690122-1%252526h%25253D1678506417%252526u%25253Dhttps%2525253A%2525252F%2525252Fprotect.checkpoint.com%2525252Fv2%2525252Fr01%2525252F___http%2525253A%2525252F%2525252Fwww.sec.gov%2525252F___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozODlkNDA2NjQzMDliNmJjZjNmYjc4MzgxMDU3YTlhMDo3OjVlN2M6MWRiMmJmY2RjNWFmMjdmMmZmOTBhNDM3YTAwNjRkM2E4OGM4ZWY2NDJmY2ExZWFlMTIwOWVkN2JhNTM1ZjcxZTpwOlQ6Rg%252526a%25253Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjdmODdiYmY0NjY2NzU4NzgzZWIyNDI3ODg4MTZiMGVlOjc6MDIyZDplNDhjNWE4M2FhNjI2OTc4MDc0ZjUzNTY2YzA1YzgzN2MwZmQ2ZDIxMTc1N2U3ODZhODk2NzQzZjc4MzY0MTNkOnA6RjpG%2526a%253Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjYwOTNjNzI3MDdjNDk5NmFhYzcxYjZmMDdjODE4ZDA0Ojc6ZTU5MzozZjQ1ZDAzYmViZmQ0MzliMGZkZjA5NDJhMmY3OTQ0MWQ4ZTBmNWJmZmM5MWFjZWVkNWIxNzA4ZDA1Nzc3ZjgwOnA6RjpG%26a%3Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmRkZDMyYWMyOWNlOTIyZTVkNDQzOWU3MjZiOTA4NzQ2Ojc6YzFhZTo5NWVjYzAzYTc1ZDIyMzkxMGZkZGRiNjAyZGU2MWI3Y2RlYjZhMmM2MTNlMjdjY2VmNGMzOTViNzU2Y2U0NDdlOnA6RjpG&a=www.sec.gov)\n.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4805907-1&h=2430983653&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4789062-1%26h%3D2428445157%26u%3Dhttps%253A%252F%252Fprotect.checkpoint.com%252Fv2%252Fr01%252F___https%253A%252Fedge.prnewswire.com%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4772576-1%2526h%253D4152424364%2526u%253Dhttps%25253A%25252F%25252Fprotect.checkpoint.com%25252Fv2%25252Fr01%25252F___https%25253A%25252Fedge.prnewswire.com%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4690122-1%252526h%25253D1678506417%252526u%25253Dhttps%2525253A%2525252F%2525252Fprotect.checkpoint.com%2525252Fv2%2525252Fr01%2525252F___http%2525253A%2525252F%2525252Fwww.sec.gov%2525252F___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozODlkNDA2NjQzMDliNmJjZjNmYjc4MzgxMDU3YTlhMDo3OjVlN2M6MWRiMmJmY2RjNWFmMjdmMmZmOTBhNDM3YTAwNjRkM2E4OGM4ZWY2NDJmY2ExZWFlMTIwOWVkN2JhNTM1ZjcxZTpwOlQ6Rg%252526a%25253Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjdmODdiYmY0NjY2NzU4NzgzZWIyNDI3ODg4MTZiMGVlOjc6MDIyZDplNDhjNWE4M2FhNjI2OTc4MDc0ZjUzNTY2YzA1YzgzN2MwZmQ2ZDIxMTc1N2U3ODZhODk2NzQzZjc4MzY0MTNkOnA6RjpG%2526a%253Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjYwOTNjNzI3MDdjNDk5NmFhYzcxYjZmMDdjODE4ZDA0Ojc6ZTU5MzozZjQ1ZDAzYmViZmQ0MzliMGZkZjA5NDJhMmY3OTQ0MWQ4ZTBmNWJmZmM5MWFjZWVkNWIxNzA4ZDA1Nzc3ZjgwOnA6RjpG%26a%3D.___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmRkZDMyYWMyOWNlOTIyZTVkNDQzOWU3MjZiOTA4NzQ2Ojc6N2Q3OTowNjAxNjc3OTEyNmQ2NDY2NzZkYjFjNTUxYjE3NzkwNDNkYTE2NWQ0M2Y2MmVjZGRiZDQ3MDM1NjRmOTE2MDZmOnA6RjpG&a=.)\n \n\nThe forward-looking statements and other information contained in this press\nrelease are made as of the date hereof, and TuHURA does not undertake any\nobligation to update publicly or revise any forward-looking statements or\ninformation, whether as a result of new information, future events or\notherwise, unless so required by applicable securities laws.\n\nInvestor Contact:\nMonique Kosse\nGilmartin Group\nMonique@GilmartinIR.com (mailto:Monique@GilmartinIR.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-provides-first-look-at-data-from-its-open-label-study-of-ifx-2-0-as-an-adjunctive-therapy-to-keytruda-in-first-line-treatment-of-patients-with-deep-seated-metastatic-merkel-cell-carcinoma-302918838.html\n(https://www.prnewswire.com/news-releases/tuhura-biosciences-provides-first-look-at-data-from-its-open-label-study-of-ifx-2-0-as-an-adjunctive-therapy-to-keytruda-in-first-line-treatment-of-patients-with-deep-seated-metastatic-merkel-cell-carcinoma-302918838.html)\n\nSOURCE TuHURA Biosciences, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS670142/TuHURA-Biosciences-Logo.jpg?id=OA3038191\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn3h5qhca-20261026","title":"TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma","author":"PR Newswire","ticker":"HURA","created":"2026-10-26T11:30:00.831Z","tickers":["HURA"],"exchange":"NASDAQ","article_body":"TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma\nPR Newswire\n\nTAMPA, Fla., Oct. 26, 2026\n\nPreliminary results demonstrate major objective tumor responses in first 3\npatients at 6 months\n\nCompany to host a webcast today, October 26, 2026, at 8:30 am ET\n\nTAMPA, Fla., Oct. 26, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:\nHURA) (\"TuHURA\" or the \"Company\"), a Phase 3 immuno-oncology company\ndeveloping novel therapeutics to overcome resistance to cancer immunotherapy,\ntoday announced initial data from the first three patients in its open-label\nstudy of IFx-2.0 as an adjunctive therapy to Keytruda® in first-line\ntreatment of metastatic Merkel Cell Carcinoma (MCC). Results showed that each\npatient achieved a major objective anti-tumor response, with all three\nresponses meeting the criteria for partial response (PR) under RECIST v.1.1\ncriteria. All responses were durable, as each of the responses were ongoing at\nthe protocol-specified six-month assessment.\n\nThe Phase 1b/2a trial of IFx-2.0 is a multicenter, open-label trial designed\nto assess the safety and feasibility of IFx-2.0 as adjunctive therapy to\nKeytruda® (pembrolizumab) when administered into deep seated and/or bulky\ntumors accessible with CT or ultrasound guided administration in the\nfront-line treatment of adult patients with metastatic MCC. The trial is\ndesigned to initially enroll a total of nine patients with visceral tumors\nincluding hepatic, pulmonary, or retroperitoneal or other deep seated\nlocations using CT or ultrasound guided administration where standard-size\ninjection needles are unable to effectively administer the intended dose of\nIFx-2.0.\n\nEach patient received IFx-2.0 (0.1 mg) injected into a single deep-seated or\nbulky tumor once a week for three weeks. Within 48 hours of the first IFx-2.0\ninjection, patients received Keytruda®, followed by Keytruda® every three\nweeks until the earlier of disease progression, toxicity, or 2 years.\nKeytruda® is approved as the front-line standard of care for patients with\nadvanced or metastatic MCC.\n\nThe primary endpoint of the study is safety and feasibility of IFx-2.0 therapy\nevaluated 28 days following the last dose of IFx-2.0, which is 49 days from\nthe first IFx-2.0 infusion. The study will also evaluate key secondary\nendpoints, including efficacy per RECIST1.1 criteria at three and six months.\n\n\"While preliminary and only reported in 3 patients, these results highlight\nthat it is feasible to utilize CT or ultrasound guided administration of\nIFx-2.0 safely to patients with large bulky and or deep-seated tumors. This is\nalso the first time we have administered IFx-2.0 with Keytruda® in the front\nline treatment setting of patients with metastatic MCC and may serve as a\nproxy to the potential response rates in the ongoing randomized placebo\ncontrolled Phase 3 trial, which is also being conducted in the front line\ntreatment of patients with advanced or metastatic MCC as an adjunct with\nKeytruda®,\" said Dr. James Bianco, President and Chief Executive Officer at\nTuHURA Biosciences. \"Approximately 30% of patients with metastatic MCC present\nwithout cutaneous or superficial nodal involvement. If we continue to see this\nhigh response rate in patients in this trial, we will explore the potential to\nexpand the number of patients in the trial and discuss with the FDA its\npotential to supplement the ongoing Phase 3 trial, should that study\nsuccessfully meet the primary endpoint. We look forward to additional patient\ndata in the coming months, and we will seek to present the data at an\nappropriate scientific conference next year.\"\n\nWebcast Information\n\nTuHURA will host a webcast today, October 26, 2026, at 8:30AM Eastern Time, to\ndiscuss the initial data from the open label Phase 1b/2a study of IFx-2.0.\n Investors and interested stakeholders may access the webcast by clicking\nHERE\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4805907-1&h=3695431808&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Ftuhura-biosciences-data-call-esmo-oct2026.open-exchange.net%2F___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQzZjFlNDNlOTU0YmIzM2YwN2Y4MWFjNjE2ZWYyZmZlOjc6MTcxMjo3NmZkZjZmMDQ5NWI2ZDRmOGE5MDYzNGEyY2Q2NTUwOGQwNGRhZTc4NzkxMDhkMzdkNTdmMWM4Yzg3ZmUyNGRiOnA6VDpG&a=HERE)\n.\n\nA replay of the webcast will be available on the Events\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4805907-1&h=83393492&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fir.tuhurabio.com%2Fnews-events%2Fevents___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQzZjFlNDNlOTU0YmIzM2YwN2Y4MWFjNjE2ZWYyZmZlOjc6YzdiZDo1N2MzMTAyNjU0NjlhMGRhMzljMDRlODY3MzU0NGJmZDJjNmZlNzk3NDg4OGQwNzE1YWYxMjBkYTA0NTFiNTFlOnA6VDpG&a=the+Events)\n portion of the Company's Investor Relation's website.\n\nAbout TuHURA Biosciences, Inc.\n\nTuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 immuno-oncology company\ndeveloping novel technologies to overcome primary and acquired resistance to\ncancer immunotherapy, two of the most common reasons cancer immunotherapies\nfail to work or stop working in the majority of patients with cancer.\n\nTuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary\nresistance to checkpoint inhibitors. TuHURA has initiated a single randomized\nplacebo-controlled Phase 3 registration trial of IFx-2.0 administered as an\nadjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus\nplacebo in first-line treatment for advanced or metastatic Merkel Cell\nCarcinoma.\n\nIn addition to its innate immune agonist product candidates, TuHURA is\ndeveloping TBS-2025, its VISTA-inhibiting mAb in a Phase 1b clinical trial in\npatients with mutNPM1 r/r AML, a molecularly defined subgroup that represents\napproximately 35% of patients with AML. TuHURA is also leveraging its Delta\nOpioid Receptor technology to develop first-in-class, bi-specific,\nbi-functional antibody drug conjugates (ADCs) targeting Myeloid-Derived\nSuppressor Cells to inhibit their immune-suppressing effects on the tumor\nmicroenvironment to prevent T cell exhaustion and acquired resistance to\ncheckpoint inhibitors and cellular therapies.\n\nFor more information, please visit www.tuhurabio.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4805907-1&h=84675304&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4767859-1%26h%3D308710934%26u%3Dhttp%253A%252F%252Fwww.tuhurabio.com%252F%26a%3Dwww.tuhurabio.com___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmRkZDMyYWMyOWNlOTIyZTVkNDQzOWU3MjZiOTA4NzQ2Ojc6NjAxNzphYmQ1NzU5MzE5NjNiNjExODUzZGRmMTAwMzQ2MjliM2U2M2VlYmJjY2U0ZWEwZTMxNTY1MjdjM2VmODYxNTNlOnA6RjpG&a=www.tuhurabio.com)\n and connect with TuHURA on Facebook, X, and LinkedIn.\n\nCautionary Statement Regarding Forward-Looking Statements\nThis press release contains certain \"forward-looking statements\" within the\nmeaning of, and subject to the safe harbor created by, Section 27A of the\nSecurities Act of 1933, as amended, Section 21E of the Securities Exchange Act\nof 1934, as amended, and the Private Securities Litigation Reform Act of 1995.\nThese forward-looking statements are based only on our current beliefs,\nexpectations and assumptions regarding the future of our business, future\nplans and strategies, projections, anticipated events and other future\nconditions. In some cases, you can identify these statements by\nforward-looking words such as \"believe,\" \"may,\" \"will,\" \"estimate,\"\n\"continue,\" \"anticipate,\" \"intend,\" \"could,\" \"should,\" \"would,\" \"project,\"\n\"plan,\" \"expect,\" \"goal,\" \"seek,\" \"future,\" \"likely,\" or the negative or\nplural of these words or similar expressions. Our statements in this press\nrelease regarding our ongoing Phase 3 study of IFx2.0 are an example of such\nforward-looking statements. You are cautioned that such statements are not\nguarantees of future performance and that actual results or developments may\ndiffer materially from those set forth in these forward-looking statements.\nFactors that could cause actual results to differ materially from these\nforward-looking statements include, among others, the risks associated\nconducting the ongoing Phase 3 study of IFx.20 and the general risks\nassociated with continuing the development of IFx2.0 and TBS 2025; risks\nrelated to patient enrollment, trial design, data outcomes and regulatory\ninteractions; uncertainty regarding the timing and likelihood of regulatory\napprovals; and the other risks described from time to time in detail in the\nCompany's Annual Report on Form 10-K for the fiscal year ended December 31,\n2025, as filed on March 31, 2026, and TuHURA's other reports and filings with\nthe SEC from time to time, which are available on TuHURA's website and at\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4805907-1&h=1954557226&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4789062-1%26h%3D1314921347%26u%3Dhttps%253A%252F%252Fprotect.checkpoint.com%252Fv2%252Fr01%252F___https%253A%252Fedge.prnewswire.com%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4772576-1%2526h%253D4152424364%2526u%253Dhttps%25253A%25252F%25252Fprotect.checkpoint.com%25252Fv2%25252Fr01%25252F___https%25253A%25252Fedge.prnewswire.com%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4690122-1%252526h%25253D1678506417%252526u%25253Dhttps%2525253A%2525252F%2525252Fprotect.checkpoint.com%2525252Fv2%2525252Fr01%2525252F___http%2525253A%2525252F%2525252Fwww.sec.gov%2525252F___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozODlkNDA2NjQzMDliNmJjZjNmYjc4MzgxMDU3YTlhMDo3OjVlN2M6MWRiMmJmY2RjNWFmMjdmMmZmOTBhNDM3YTAwNjRkM2E4OGM4ZWY2NDJmY2ExZWFlMTIwOWVkN2JhNTM1ZjcxZTpwOlQ6Rg%252526a%25253Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjdmODdiYmY0NjY2NzU4NzgzZWIyNDI3ODg4MTZiMGVlOjc6MDIyZDplNDhjNWE4M2FhNjI2OTc4MDc0ZjUzNTY2YzA1YzgzN2MwZmQ2ZDIxMTc1N2U3ODZhODk2NzQzZjc4MzY0MTNkOnA6RjpG%2526a%253Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjYwOTNjNzI3MDdjNDk5NmFhYzcxYjZmMDdjODE4ZDA0Ojc6ZTU5MzozZjQ1ZDAzYmViZmQ0MzliMGZkZjA5NDJhMmY3OTQ0MWQ4ZTBmNWJmZmM5MWFjZWVkNWIxNzA4ZDA1Nzc3ZjgwOnA6RjpG%26a%3D%25C2%25A0___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmRkZDMyYWMyOWNlOTIyZTVkNDQzOWU3MjZiOTA4NzQ2Ojc6ODE0ZDo0MDZjM2RjNzllMTJjNjNhZjEyZTljMjY0Nzk1MGJjOWI2NzRjN2RhYTVmNTNiN2U0MzJjYzM4NTZhOTA2MTFmOnA6RjpG&a=%C2%A0)\nwww.sec.gov\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4805907-1&h=3293196567&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4789062-1%26h%3D80447454%26u%3Dhttps%253A%252F%252Fprotect.checkpoint.com%252Fv2%252Fr01%252F___https%253A%252Fedge.prnewswire.com%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4772576-1%2526h%253D4152424364%2526u%253Dhttps%25253A%25252F%25252Fprotect.checkpoint.com%25252Fv2%25252Fr01%25252F___https%25253A%25252Fedge.prnewswire.com%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4690122-1%252526h%25253D1678506417%252526u%25253Dhttps%2525253A%2525252F%2525252Fprotect.checkpoint.com%2525252Fv2%2525252Fr01%2525252F___http%2525253A%2525252F%2525252Fwww.sec.gov%2525252F___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozODlkNDA2NjQzMDliNmJjZjNmYjc4MzgxMDU3YTlhMDo3OjVlN2M6MWRiMmJmY2RjNWFmMjdmMmZmOTBhNDM3YTAwNjRkM2E4OGM4ZWY2NDJmY2ExZWFlMTIwOWVkN2JhNTM1ZjcxZTpwOlQ6Rg%252526a%25253Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjdmODdiYmY0NjY2NzU4NzgzZWIyNDI3ODg4MTZiMGVlOjc6MDIyZDplNDhjNWE4M2FhNjI2OTc4MDc0ZjUzNTY2YzA1YzgzN2MwZmQ2ZDIxMTc1N2U3ODZhODk2NzQzZjc4MzY0MTNkOnA6RjpG%2526a%253Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjYwOTNjNzI3MDdjNDk5NmFhYzcxYjZmMDdjODE4ZDA0Ojc6ZTU5MzozZjQ1ZDAzYmViZmQ0MzliMGZkZjA5NDJhMmY3OTQ0MWQ4ZTBmNWJmZmM5MWFjZWVkNWIxNzA4ZDA1Nzc3ZjgwOnA6RjpG%26a%3Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmRkZDMyYWMyOWNlOTIyZTVkNDQzOWU3MjZiOTA4NzQ2Ojc6YzFhZTo5NWVjYzAzYTc1ZDIyMzkxMGZkZGRiNjAyZGU2MWI3Y2RlYjZhMmM2MTNlMjdjY2VmNGMzOTViNzU2Y2U0NDdlOnA6RjpG&a=www.sec.gov)\n.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4805907-1&h=2430983653&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4789062-1%26h%3D2428445157%26u%3Dhttps%253A%252F%252Fprotect.checkpoint.com%252Fv2%252Fr01%252F___https%253A%252Fedge.prnewswire.com%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4772576-1%2526h%253D4152424364%2526u%253Dhttps%25253A%25252F%25252Fprotect.checkpoint.com%25252Fv2%25252Fr01%25252F___https%25253A%25252Fedge.prnewswire.com%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4690122-1%252526h%25253D1678506417%252526u%25253Dhttps%2525253A%2525252F%2525252Fprotect.checkpoint.com%2525252Fv2%2525252Fr01%2525252F___http%2525253A%2525252F%2525252Fwww.sec.gov%2525252F___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozODlkNDA2NjQzMDliNmJjZjNmYjc4MzgxMDU3YTlhMDo3OjVlN2M6MWRiMmJmY2RjNWFmMjdmMmZmOTBhNDM3YTAwNjRkM2E4OGM4ZWY2NDJmY2ExZWFlMTIwOWVkN2JhNTM1ZjcxZTpwOlQ6Rg%252526a%25253Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjdmODdiYmY0NjY2NzU4NzgzZWIyNDI3ODg4MTZiMGVlOjc6MDIyZDplNDhjNWE4M2FhNjI2OTc4MDc0ZjUzNTY2YzA1YzgzN2MwZmQ2ZDIxMTc1N2U3ODZhODk2NzQzZjc4MzY0MTNkOnA6RjpG%2526a%253Dwww.sec.gov___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjYwOTNjNzI3MDdjNDk5NmFhYzcxYjZmMDdjODE4ZDA0Ojc6ZTU5MzozZjQ1ZDAzYmViZmQ0MzliMGZkZjA5NDJhMmY3OTQ0MWQ4ZTBmNWJmZmM5MWFjZWVkNWIxNzA4ZDA1Nzc3ZjgwOnA6RjpG%26a%3D.___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OmRkZDMyYWMyOWNlOTIyZTVkNDQzOWU3MjZiOTA4NzQ2Ojc6N2Q3OTowNjAxNjc3OTEyNmQ2NDY2NzZkYjFjNTUxYjE3NzkwNDNkYTE2NWQ0M2Y2MmVjZGRiZDQ3MDM1NjRmOTE2MDZmOnA6RjpG&a=.)\n \n\nThe forward-looking statements and other information contained in this press\nrelease are made as of the date hereof, and TuHURA does not undertake any\nobligation to update publicly or revise any forward-looking statements or\ninformation, whether as a result of new information, future events or\notherwise, unless so required by applicable securities laws.\n\nInvestor Contact:\nMonique Kosse\nGilmartin Group\nMonique@GilmartinIR.com (mailto:Monique@GilmartinIR.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-provides-first-look-at-data-from-its-open-label-study-of-ifx-2-0-as-an-adjunctive-therapy-to-keytruda-in-first-line-treatment-of-patients-with-deep-seated-metastatic-merkel-cell-carcinoma-302918838.html\n(https://www.prnewswire.com/news-releases/tuhura-biosciences-provides-first-look-at-data-from-its-open-label-study-of-ifx-2-0-as-an-adjunctive-therapy-to-keytruda-in-first-line-treatment-of-patients-with-deep-seated-metastatic-merkel-cell-carcinoma-302918838.html)\n\nSOURCE TuHURA Biosciences, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS670142/TuHURA-Biosciences-Logo.jpg?id=OA3038191\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-26T11:30:00.967727894Z","server_sent_at_ms":1793014200967},"received_at":"2026-10-26T11:30:01.057Z","source_url":"https://www.prnewswire.com/news-releases/tuhura-biosciences-provides-first-look-at-data-from-its-open-label-study-of-ifx-2-0-as-an-adjunctive-therapy-to-keytruda-in-first-line-treatment-of-patients-with-deep-seated-metastatic-merkel-cell-carcinoma-302918838.html"},"analysis":{"id":"167339","press_release_id":"179455","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["data limited to 3 patients in an open-label, non-controlled study","responses are partial, not complete; no progression-free or overall survival data","primary endpoint is safety/feasibility, not efficacy"],"eventType":"clinical_trial","narrative":"TuHURA Biosciences reported initial data from the first three patients in its open-label Phase 1b/2a study of IFx-2.0 plus Keytruda in first-line metastatic Merkel Cell Carcinoma.\n\nAll three patients achieved partial responses per RECIST v1.1, with every response ongoing at the protocol-specified six-month assessment, and CT/ultrasound-guided administration was shown to be safe and feasible in deep-seated bulky tumors.\n\nManagement framed the results as a proxy for the ongoing randomized placebo-controlled Phase 3 trial and said it would explore expanding enrollment and discussing the data with the FDA if responses hold.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"3-for-3 durable partial responses in first-line MCC strengthen the case for IFx-2.0 ahead of the pivotal Phase 3 readout."},"keyFigures":{"drugName":"IFx-2.0","phaseOfTrial":"Phase 1b/2a","customDimensions":{"ifx_dose":"0.1 mg weekly for 3 weeks into a single deep-seated tumor","responses":"3/3 partial responses (RECIST v1.1), ongoing at 6-month assessment","indication":"first-line metastatic Merkel Cell Carcinoma","patients_reported":3,"planned_enrollment":9}},"quotedText":"While preliminary and only reported in 3 patients, these results highlight that it is feasible to utilize CT or ultrasound guided administration of IFx-2.0 safely to patients with large bulky and or deep-seated tumors.","namedEntities":{"people":[{"name":"Dr. James Bianco","role":"President and CEO"},{"name":"Monique Kosse","role":"Investor Contact, Gilmartin Group"}],"products":["IFx-2.0","Keytruda (pembrolizumab)","TBS-2025"],"companies":[{"name":"TuHURA Biosciences, Inc.","ticker":"HURA","relationship":"filer"},{"name":"Merck (Keytruda/pembrolizumab)","relationship":"partner drug / combination therapy"},{"name":"Gilmartin Group","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"First-in-human combination data showing all 3 initial patients achieved durable partial responses per RECIST v1.1, a positive read-through for the ongoing pivotal Phase 3 of IFx-2.0 plus Keytruda. However, the dataset is only 3 patients from an open-label study, limiting definitive impact."},"tickerRelevance":{"others":[],"primary":"HURA"},"globalImportance":30,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"early clinical data n=3","sectorWeight":"biotech clinical catalyst","sampleSizeLimit":true}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"TuHURA Biosciences reported initial data from the first three patients in its open-label Phase 1b/2a study of IFx-2.0 plus Keytruda in first-line metastatic Merkel Cell Carcinoma.\n\nAll three patients achieved partial responses per RECIST v1.1, with every response ongoing at the protocol-specified six-month assessment, and CT/ultrasound-guided administration was shown to be safe and feasible in deep-seated bulky tumors.\n\nManagement framed the results as a proxy for the ongoing randomized placebo-controlled Phase 3 trial and said it would explore expanding enrollment and discussing the data with the FDA if responses hold.","key_figures":{"drugName":"IFx-2.0","phaseOfTrial":"Phase 1b/2a","customDimensions":{"ifx_dose":"0.1 mg weekly for 3 weeks into a single deep-seated tumor","responses":"3/3 partial responses (RECIST v1.1), ongoing at 6-month assessment","indication":"first-line metastatic Merkel Cell Carcinoma","patients_reported":3,"planned_enrollment":9}},"named_entities":{"people":[{"name":"Dr. James Bianco","role":"President and CEO"},{"name":"Monique Kosse","role":"Investor Contact, Gilmartin Group"}],"products":["IFx-2.0","Keytruda (pembrolizumab)","TBS-2025"],"companies":[{"name":"TuHURA Biosciences, Inc.","ticker":"HURA","relationship":"filer"},{"name":"Merck (Keytruda/pembrolizumab)","relationship":"partner drug / combination therapy"},{"name":"Gilmartin Group","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-26T11:30:13.087Z","global_importance":30,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"early clinical data n=3","sectorWeight":"biotech clinical catalyst","sampleSizeLimit":true}},"durationMs":6261,"modelName":"glm-5.3-flashx"}}